Wuerzner Grégoire, Waeber Bernard
Service de Néphrologie et Hypertension, CHUV, Lausanne.
Faculté de biologie et de médecine, Université de Lausanne.
Praxis (Bern 1994). 2021 Feb;110(2):1-5. doi: 10.1024/1661-8157/a003639.
Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice The COVID-19 pandemic represents a major public health problem. A fraction of the population is at increased risk of developing complications of this disease, in particular older subjects as well as diabetic, obese and hypertensive patients. With regard to patients with high blood pressure, the existence of an increased risk remains to be confirmed in large controlled trials. So far the findings regarding this question are reassuring, whether these patients are treated or not. There seems to be no reason to worry when using blockers of the renin-angiotensin system. The observations available to date suggest that COVID-19 vaccine can be administered safely to hypertensive patients. In conclusion, there is no reason to implement changes in the care of hypertensive patients due to the pandemic.
高血压与新冠疫情:医疗实践中应考虑的问题 新冠疫情是一个重大的公共卫生问题。一部分人群患此病并发症的风险增加,尤其是老年患者以及糖尿病、肥胖和高血压患者。对于高血压患者,在大型对照试验中,其风险增加这一情况仍有待证实。到目前为止,无论这些患者是否接受治疗,关于这个问题的研究结果都令人安心。使用肾素 - 血管紧张素系统阻滞剂似乎没有理由担心。迄今为止的观察结果表明,新冠疫苗可安全地接种给高血压患者。总之,由于疫情,没有理由对高血压患者的治疗进行改变。